PTCT Stock Overview
A biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
PTC Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$39.36 |
| 52 Week High | US$46.98 |
| 52 Week Low | US$20.75 |
| Beta | 0.63 |
| 11 Month Change | 2.39% |
| 3 Month Change | 17.74% |
| 1 Year Change | 82.05% |
| 33 Year Change | -0.13% |
| 5 Year Change | -15.70% |
| Change since IPO | 138.69% |
Recent News & Updates
Recent updates
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Fly 29% But Investors Aren't Buying For Growth
Oct 09
PTC Therapeutics: Positive HD Data Along With NDA Submission Brings Further Value
Sep 12Little Excitement Around PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Revenues
Jun 28PTC Therapeutics: Riding The Regulatory Rollercoaster With Translarna
May 22Industry Analysts Just Upgraded Their PTC Therapeutics, Inc. (NASDAQ:PTCT) Revenue Forecasts By 11%
May 22PTC Therapeutics: Multiple Regulatory Submissions Along With Data Cuts
May 14PTC Therapeutics, Inc. (NASDAQ:PTCT) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Mar 03PTC Therapeutics: Already Generates Revenues, But Lots Of Outstanding Options
Feb 11An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued
Jun 23Benign Growth For PTC Therapeutics, Inc. (NASDAQ:PTCT) Underpins Its Share Price
May 18An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued
Mar 02PTC pauses enrollment in mid-stage study for Huntington's disease candidate in U.S.
Oct 19PTC Therapeutics betas topline expectations, strengthens commercial portfolio
Aug 05PTC Therapeutics gene therapy Upstaza wins approval in EU for ultra-rare neuromuscular disorder
Jul 20PTC Therapeutics: DMD Trial News Unlikely To Restore Flagging Share Price
Jun 24Shareholder Returns
| PTCT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -10.6% | -7.5% | -1.2% |
| 1Y | 82.1% | 14.1% | 30.4% |
Return vs Industry: PTCT exceeded the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: PTCT exceeded the US Market which returned 30.4% over the past year.
Price Volatility
| PTCT volatility | |
|---|---|
| PTCT Average Weekly Movement | 7.7% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PTCT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: PTCT's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 1,022 | Matt Klein | www.ptcbio.com |
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington’s disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis.
PTC Therapeutics, Inc. Fundamentals Summary
| PTCT fundamental statistics | |
|---|---|
| Market cap | US$3.04b |
| Earnings (TTM) | -US$453.20m |
| Revenue (TTM) | US$900.66m |
3.4x
P/S Ratio-6.7x
P/E RatioIs PTCT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PTCT income statement (TTM) | |
|---|---|
| Revenue | US$900.66m |
| Cost of Revenue | US$601.30m |
| Gross Profit | US$299.37m |
| Other Expenses | US$752.57m |
| Earnings | -US$453.20m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.88 |
| Gross Margin | 33.24% |
| Net Profit Margin | -50.32% |
| Debt/Equity Ratio | -224.5% |
How did PTCT perform over the long term?
See historical performance and comparison